North Growth Management’s Charles River Laboratories CRL Stock Holding History

North Growth Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-39,000	Closed	-$5.87M	–	48
2025 Q1	$5.87M	Hold	39,000	–	–	1.24%	33
2024 Q4	$7.17M	Buy	39,000 +6,000	+18%	+$1.16M	1.36%	33
2024 Q3	$6.45M	Hold	33,000	–	–	1.2%	37
2024 Q2	$6.75M	Hold	33,000	–	–	1.33%	34
2024 Q1	$8.84M	Sell	33,000 -4,000	-11%	-$955K	1.69%	27
2023 Q4	$8.76M	Hold	37,000	–	–	1.87%	26
2023 Q3	$7.26M	Buy	37,000 +5,000	+16%	+$1.03M	1.61%	29
2023 Q2	$6.65M	Buy	32,000 +8,000	+33%	+$1.59M	1.37%	35
2023 Q1	$4.76M	Buy	+24,000	New	+$5.44M	1.01%	39

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

North Growth Management's CRL Position: Q2 2025 in Review

North Growth Management sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 39,000 shares — an estimated $5.87M sold.

North Growth Management first reported a position in CRL in Q1 2023 and held it in 9 quarters. The position peaked at $8.84M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

North Growth Management reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
North Growth Management sold 39,000 Charles River Laboratories shares in Q2 2025, an estimated $5.87M.
North Growth Management first reported a position in Charles River Laboratories in Q1 2023 and held it in 9 quarters.
North Growth Management's Charles River Laboratories position peaked at $8.84M in Q1 2024.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on North Growth Management's 13F filing for Q2 2025, filed 13 Aug 2025.